Phase 2 Trial of CXA-10 Recruiting Patients

This topic contains 0 replies, has 1 voice, and was last updated by  Kathleen Sheffer 3 months, 3 weeks ago.

  • Author
    Posts
  • #15931
     Kathleen Sheffer 
    Keymaster

    Complexa Starts Dosing in Phase 2 Trial to Evaluate CXA-10 for PAH

    Yesterday Complexa Inc. announced dosing of the first patient in its Phase 2 clinical trial, PRIMEx. The trial evaluates the safety and efficacy of two doses of the company’s lead candidate, CXA-10 to treat pulmonary arterial hypertension (PAH).

    The study includes approximately 45 centers across the United States and Europe. These centers are currently recruiting an anticipated 115 subjects whose involvement will last about five months. Visit the clinical trial’s official website to learn more and find an institution near you.

    “We are pleased to advance CXA-10 and continue clinical evaluation of this exciting compound, which has the potential to be a novel first-in-class treatment for patients living with PAH,” Francisco Salva, president and CEO of Complexa, said in a press release.

    CXA-10 is an oral nitrated fatty acid (NFA) compound that impacts the fibrotic and inflammatory pathways. NFAs, a novel class of compounds, have demonstrated broad potential to be disease-modifying in many disorders. Complexa’s research builds on a growing trend in PAH drug development that targets inflammation.

    “Currently, approved [PAH] treatment options primarily target symptoms without appreciable impact on modifying the underlying disease,” Salva said. “With CXA-10, we have the opportunity to address the unresolved need in PAH.”

    Results from the Phase 1 trial gave evidence of CXA-10’s targeted activity, and Phase 1b demonstrated safety and tolerability in all 97 participants.

    Do you think you might qualify for this clinical trial? What questions do you have about this new class of treatment for PAH?

You must be logged in to reply to this topic.

Copyright © 2017-2019 All rights reserved.

©2019 KLEO Template a premium and multipurpose theme from Seventh Queen

CONTACT US

We're not around right now. But you can send us an email and we'll get back to you, asap.

Sending
or

Log in with your credentials

or    

Forgot your details?

or

Create Account